In April 2022, the Biden administration ordered 20 million doses of Pfizer’s antiviral Covid-19 treatment called Paxlovid.
Now a study published in the New England Journal of Medicine shows the medication shows “no measurable benefit” for the treatment of COVID-19 in patients 40 to 65-years of age.
WASHINGTON — Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
The results from a 109,000-patient Israeli study are likely to renew questions about the U.S. government’s use of Paxlovid, which has become the go-to treatment for COVID-19 due to its at-home convenience. The Biden administration has spent more than $10 billion purchasing the drug and making it available at thousands of pharmacies through its test-and-treat initiative.
[

Additionally, Biden has extended the “COVID emergency payment moratorium” through the end of the year. No one with a federal student loan needs to restart paying until after the midterm election, in 2023. [